{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:14:08Z","timestamp":1785726848439,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Education and scientific research project for middle-aged and young teachers in Fujian province","award":["JAT241037"],"award-info":[{"award-number":["JAT241037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10787-025-02066-5","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T01:12:51Z","timestamp":1770426771000},"page":"1763-1773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitis"],"prefix":"10.1007","volume":"34","author":[{"given":"Yaping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2729","authenticated-orcid":false,"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"2066_CR1","unstructured":"Abrocitinib label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s004lblcorrected.pdf."},{"key":"2066_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"3","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannen L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A (2019) Conjunctivitis in dupilumab clinical trials. Br J Dermatol 3:459\u2013473. https:\/\/doi.org\/10.1111\/bjd.17869","journal-title":"Br J Dermatol"},{"key":"2066_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.010","author":"G Balakirski","year":"2022","unstructured":"Balakirski G, Novak N (2022) Atopic dermatitis and pregnancy. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.010","journal-title":"J Allergy Clin Immunol"},{"key":"2066_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L (2018) Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. https:\/\/doi.org\/10.1111\/all.13401","journal-title":"Allergy"},{"key":"2066_CR5","unstructured":"Baricitinib label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf."},{"key":"2066_CR6","unstructured":"Baricitinib. EU summary of product characteristic. December 2, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf."},{"key":"2066_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H (2021) Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2019380","journal-title":"N Engl J Med"},{"key":"2066_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2161812","volume":"1","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Tha\u00e7i D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP (2023) Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat 1:2161812. https:\/\/doi.org\/10.1080\/09546634.2022.2161812","journal-title":"J Dermatolog Treat"},{"key":"2066_CR9","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/s0140-6736(17)31191-1","volume":"10086","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kem\u00e9ny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 10086:2287\u20132303. https:\/\/doi.org\/10.1016\/s0140-6736(17)31191-1","journal-title":"Lancet"},{"key":"2066_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K (2021) Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","journal-title":"JAMA Dermatol"},{"key":"2066_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad022","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI (2023) Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. https:\/\/doi.org\/10.1093\/bjd\/ljad022","journal-title":"Br J Dermatol"},{"key":"2066_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.03.011","author":"S Butala","year":"2023","unstructured":"Butala S, Castelo-Soccio L, Seshadri R, Simpson EL, O\u2019Shea JJ, Bieber T, Paller AS (2023) Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations. J Allergy Clin Immunol Pract. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2066_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107966","author":"M Chen","year":"2024","unstructured":"Chen M, Huang Y, Jiang S, Ke C (2024a) Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: a real-world pharmacovigilance study. Lung Cancer. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107966","journal-title":"Lung Cancer"},{"key":"2066_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116546","author":"M Chen","year":"2024","unstructured":"Chen M, Ke C, Huang Y (2024b) Herpes virus reactivation induced by abrocitinib: a real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Diagn Microbiol Infect Dis. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116546","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2066_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2021.1940962","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E (2021) The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666x.2021.1940962","journal-title":"Expert Rev Clin Immunol"},{"key":"2066_CR16","unstructured":"Dupilumab label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s059lbl.pdf."},{"key":"2066_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/all.12270","author":"C Flohr","year":"2014","unstructured":"Flohr C, Mann J (2014) New insights into the epidemiology of childhood atopic dermatitis. Allergy. https:\/\/doi.org\/10.1111\/all.12270","journal-title":"Allergy"},{"key":"2066_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.09.023","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD (2023) Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023","journal-title":"J Allergy Clin Immunol"},{"key":"2066_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, Zarour A, Michel M, Cohen JL, Amiot A, Claudepierre P, Wolkenstein P, Grimbert P, Sbidian E (2022) Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-10777-w","journal-title":"Sci Rep"},{"key":"2066_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/2168479013514236","author":"L Huang","year":"2014","unstructured":"Huang L, Guo T, Zalkikar JN, Tiwari RC (2014) A review of statistical methods for safety surveillance. Ther Innov Regul Sci. https:\/\/doi.org\/10.1177\/2168479013514236","journal-title":"Ther Innov Regul Sci"},{"key":"2066_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB (2022) JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"},{"key":"2066_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ijc.35193","volume":"35","author":"C Ke","year":"2024","unstructured":"Ke C, Chen M, Lin L, Huang Y (2024) Postmarketing adverse events of tamoxifen in male and female patients with breast cancer. Int J Cancer. 35:193. https:\/\/doi.org\/10.1002\/ijc.35193","journal-title":"Int J Cancer."},{"key":"2066_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00837-w","author":"RW Kim","year":"2024","unstructured":"Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM (2024) Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-023-00837-w","journal-title":"Am J Clin Dermatol"},{"key":"2066_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19580","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, Dellavalle RP, Flohr C (2021) The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.19580","journal-title":"Br J Dermatol"},{"key":"2066_CR25","unstructured":"Lebrikizumab label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761306Orig1s000correctedlbl.pdf."},{"key":"2066_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.644760","author":"FJ Legat","year":"2021","unstructured":"Legat FJ (2021) Itch in Atopic Dermatitis - what is new? Front Med. https:\/\/doi.org\/10.3389\/fmed.2021.644760","journal-title":"Front Med"},{"key":"2066_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825312","author":"J Liang","year":"2022","unstructured":"Liang J, Hu F, Dan M, Sang Y, Abulikemu K, Wang Q, Hong Y, Kang X (2022) Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.825312","journal-title":"Front Immunol"},{"key":"2066_CR28","volume":"8","author":"A Mesjasz","year":"2023","unstructured":"Mesjasz A, Ko\u0142kowski K, Wollenberg A, Trzeciak M (2023) How to understand personalized medicine in atopic dermatitis nowadays? Int J Mol Sci 8:10.3390\/ijms24087557","journal-title":"Int J Mol Sci"},{"key":"2066_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000003162","author":"T Mickevicius","year":"2023","unstructured":"Mickevicius T, Pink AE, Bhogal M, O\u2019Brart D, Robbie SJ (2023) Dupilumab-induced, tralokinumab-induced, and belantamab mafodotin-induced adverse ocular events-incidence, etiology, and management. Cornea. https:\/\/doi.org\/10.1097\/ico.0000000000003162","journal-title":"Cornea"},{"key":"2066_CR30","unstructured":"Nemolizumab label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761390s000lbl.pdf."},{"key":"2066_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085","journal-title":"J Am Acad Dermatol"},{"key":"2066_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, Kuligowski ME, Kallender H, Sun K, Ren H, Simpson EL (2023) Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060","journal-title":"J Am Acad Dermatol"},{"key":"2066_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.17192","volume":"2","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D\u2019Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D\u2019Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F (2021) Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2:356\u2013368. https:\/\/doi.org\/10.1111\/bjh.17192","journal-title":"Br J Haematol"},{"key":"2066_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01199-0","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U (2022) Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(22)01199-0","journal-title":"Lancet"},{"key":"2066_CR35","unstructured":"Ruxolitinib label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215309s004lbl.pdf."},{"key":"2066_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG (2023) A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). https:\/\/doi.org\/10.1007\/s13555-023-00892-5","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2066_CR37","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.jaip.2022.08.013","volume":"12","author":"F Shakuntulla","year":"2022","unstructured":"Shakuntulla F, Chiarella SE (2022) Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol Pract 12:3149\u20133155. https:\/\/doi.org\/10.1016\/j.jaip.2022.08.013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2066_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2016696","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Dai B, Zhang Q (2022a) A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2022.2016696","journal-title":"Expert Opin Drug Saf"},{"key":"2066_CR39","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S365513","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022b) A real-world disproportionality analysis of Olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. https:\/\/doi.org\/10.2147\/clep.S365513","journal-title":"Clin Epidemiol"},{"key":"2066_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S (2021) Integrated safety analysis of Abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-021-00618-3","journal-title":"Am J Clin Dermatol"},{"key":"2066_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21867","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sall\u00e9 D, Girolomoni G, Papp K, de Bruin-Weller M, Thyssen JP, Zachariae R, Olsen CK, Wollenberg A (2022) Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.21867","journal-title":"Br J Dermatol"},{"key":"2066_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00245-0","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P (2020) Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. https:\/\/doi.org\/10.1007\/s40744-020-00245-0","journal-title":"Rheumatol Ther"},{"key":"2066_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S (2021) Atopic Dermatitis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMra2023911","journal-title":"N Engl J Med"},{"key":"2066_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.11477\/mf.1416201783","volume":"5","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y (2021) [Recent Perspectives for Targeted Therapies]. Brain Nerve 5:431\u2013440. https:\/\/doi.org\/10.11477\/mf.1416201783","journal-title":"Brain Nerve"},{"key":"2066_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12817","author":"E Thomaidou","year":"2019","unstructured":"Thomaidou E, Ramot Y (2019) Injection site reactions with the use of biological agents. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.12817","journal-title":"Dermatol Ther"},{"key":"2066_CR46","unstructured":"Tralokinumab label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761180s006lbl.pdf."},{"key":"2066_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2690","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA (2018) Risk factors for Dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2690","journal-title":"JAMA Dermatol"},{"key":"2066_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/all.16265","author":"SY Tsai","year":"2024","unstructured":"Tsai SY, Gaffin JM, Hawryluk EB, Ruran HB, Bartnikas LM, Oyoshi MK, Schneider LC, Phipatanakul W, Ma KS (2024) Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study. Allergy. https:\/\/doi.org\/10.1111\/all.16265","journal-title":"Allergy"},{"key":"2066_CR49","unstructured":"Upadacitinib label. Food and Drug Administration. Accessed Nov 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218347s000lbl.pdf."},{"key":"2066_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029","journal-title":"J Allergy Clin Immunol"},{"key":"2066_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Z\u00e4ch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, G\u00e1sp\u00e1r K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C (2022) European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.18345","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2066_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01145-x","author":"HJ Yim","year":"2024","unstructured":"Yim HJ, Jean T, Ong PY (2024) Comparison of old and new systemic treatments for moderate to severe atopic dermatitis. Curr Allergy Asthma Rep. https:\/\/doi.org\/10.1007\/s11882-024-01145-x","journal-title":"Curr Allergy Asthma Rep"},{"key":"2066_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA (2022) Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02066-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:02:23Z","timestamp":1773777743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02066-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02066-5","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}